The in-vitro activity of ceftizoxime against anaerobic bacteria, especially Bacteroides fragilis, is reviewed, based on our own experience as well as on other sources. In-vitro data on ceftizoxime and other cephalosporins and related /?-lactam antibiotics against more than 500 clinical isolates of anaerobic bacteria (as determined by the NCCLS reference method) were compared at Vancouver General Hospital. Ceftizoxime exhibited excellent in-vitro activity against all anaerobes, including Bact. fragilis, when tested by the NCCLS reference method, and was comparable in activity to cefoxitin and cefotaxime. However, marked variation in susceptibility results was noted against Bact. fragilis and the Bact. fragilis group, primarily related to the size of inoculum and type of media utilized in the different studies. With the supplemented brucella agar technique, ceftizoxime was distinctly less active against the Bact. fragilis group. These data underscore the importance of standardized techniques for in-vitro susceptibility testing of anaerobes. Further in-vitro and clinical studies are clearly indicated.
Introduction
Ceftizoxime and a number of other new cephalosporins are characterized by their stability to /3-lactamase inactivation, and their markedly enhanced in-vitro activity against a wide variety of micro-organisms, including anaerobic bacteria Drulak & Chow, 1981) . However, because of methodological differences, limited numbers of strains tested, and regional variations in susceptibility patterns, it has often been difficult to compare such in-vitro data from study to study, especially for anaerobic bacteria, to ascertain differences in susceptibility among different genera or species of anaerobes, and to place in proper perspective the relative anti-anaerobic spectrum of these new /Mactam agents. We have, therefore, reviewed all the available invitro data of the antibacterial activity of ceftizoxime against obligate anaerobes, particularly Bacteroides fragilis. Differences in testing procedures, especially inoculum size and type of media, are noted where appropriate. In addition, the experience at Vancouver General Hospital with the comparative in-vitro activity of ceftizoxime and other new cephalosporins including cefotaxime, moxalactam, cefoperazone, cefuroxime, ceftazidime, as well as cefoxitin against more than 500 clinical isolates of anaerobic presented.
Materials and methods
The in-vitro activity of ceftizoxime against Bad. fragilis was summarized from data published from 1979 to 1982. The following criteria were used in compiling the data: only results from clinical isolates were included; only discrete minimum inhibitory concentration (MIC) values were used; when data were presented in graphic form, MIC values were computed; repetition of data was avoided; data on species and subspecies were consolidated in some cases.
Comparative in-vitro activity of ceftizoxime and other cephalosporins against a wide variety of clinical isolates of obligate anaerobes were summarized from data obtained from the laboratory of one of the authors (A.W.C.). Isolates examined were obtained from inpatients of Harbor-UCLA Medical Center and Vancouver General Hospital, British Columbia, Canada, during 1975 to 1981. Identification at the species level was carried out in prereduced, anaerobically sterilized (PRAS) differential media by the methods of Holdeman, Cato & Moore (1977) . The isolates were stored in 20% skim milk and frozen at -75°C until ready for antibiotic susceptibility testing. Susceptibility to the /Mactam agents was determined by an agar-dilution technique on Wilkins-Chalgren media supplemented with haemin (5 mg/1) and vitamin K, (10 mg/1) according to the method of Sutter et al. (1979) . Two-fold serial dilutions of ceftizoxime, cefotaxime, moxalactam, cefoperazone, cefuroxime, ceftazidime, and cefoxitin were added to obtain final antibiotic concentrations ranging from 025 to 128 mg/1. A 48-h subculture of the test organism in PRAS thioglycollate broth was adjusted to a McFarland number 0-5 nephelometer standard (Finegold, Martin & Scott, 1978) , previously determined to approximate 10 8 cfu/ml by pour plate techniques. Inocula (00025 ml) of 10 5 cfu were delivered with a Steers inocula replicator (Steers et al., 1959) . Plates were incubated at 37°C in anaerobic jars with a gas mixture containing 80% nitrogen, 10% hydrogen, and 10% carbon dioxide. Anaerobic, micro-aerophilic (incubated in candle jars) and aerobic plates without antibiotics were used for controls, and two reference strains {Bact. fragilis VGH-3186 and Clostridium perfringens VGH-3000) with known minimal inhibitory concentrations (MIC) were included in each test for reproducibility. All results were read at 48 h of incubation, and the MIC values recorded were the lowest antibiotic concentration which yielded no visible growth.
Results and discussion
The in-vitro activity of ceftizoxime against Bact. fragilis and the Bad. fragilis group (includes Bact. fragilis, Bact. distasonis. Bact. vulgatus, Bact. thetaiotaomicron, Bact. ovatus, and Bact. fragilis, other) as compiled from available data, and the respective sources of information as well as known conditions of the testing procedure are summarized in Table I . As can be seen, both the inoculum size and type of media used strongly affect the susceptibility results. In general, Wilkins-Chalgren, Mueller-Hinton, and brain heart infusion media gave comparable results for Bact.fragilis strains when an inoculum of 10 s cfu was used in an agar dilution technique. GAM agar inoculated with 10 values. This finding was confirmed by Yokota (1979) who compared the MICs of eight strains of Bact. fragilis as determined either in Wilkins-Chalgren, brain heart infusion, GAM, or brucella blood agar, using identical inocula of 10 6 cfu/ml. The geometric mean MIC in brucella blood agar was 50-fold that in Wilkins-Chalgren agar, 40-fold that in GAM agar, and sevenfold that in brain heart infusion agar. These data underscore the importance of standardized techniques for in-vitro susceptibility testing of anaerobic bacteria, and the need to include reference strains in the reporting of data in order that comparisons between different studies may be more meaningful. Results of in-vitro susceptibility of the Bact. fragilis group are even more variable, probably because of the heterogeneity of the strains included in different studies. Drulak & Chow (1981) noted considerable variation in susceptibility to ceftizoxime within the Bact. fragilis group. Bact. fragilis was considerably more resistant than Bact. vulgatus and Bact. distasonis, and was comparable in susceptibility to Bact. thetaiotaomicron.
The marked inoculum effect observed with ceftizoxime against Bact. fragilis may be related to the fact that, despite its enhanced stability to most /J-lactamases, hydrolysis of ceftizoxime by some /Mactamases from Bact. fragilis may still occur, as has been reported by Sato et al. (1980) and Yokota (1979) . Such an inoculum effect is not observed with cefoxitin which appears virtually resistant to hydrolyis by /?-lactamases of Bact. fragilis (Darland & Birnbaum, 1977; Tally et al., 1979) . It has been suggested that the 7a-methoxy-substitution in cefoxitin may account for its unique resistance to and inactivation of /?-lactamases from Bact. fragilis (Sato et al., 1980) .
The in-vitro activity of ceftizoxime against more than 500 clinical isolates of anaerobic bacteria as determined in Vancouver by the NCCLS reference method (Sutter et al., 1979) is summarized in Table II and compared with other related /Mactams (cefoxitin, cefotaxime, moxalactam, cefoperazone, cefuroxime, and ceftazidime). Overall, ceftizoxime, cefotaxime, and cefoxitin were comparable in activity and were the most active among the cephalosporins tested (MIC 90 of 27, 33 and 29 mg/1, respectively). Cefoperazone and moxalactam were moderately active (MIC 90 of 40 and 64 mg/1, respectively). Cefuroxime and ceftazidime were least active (MIC 90 of 107 and > 128 mg/1, respectively). Against the species of Bact. fragilis, however, cefoxitin remained the most active, followed by moxalactam, ceftizoxime, and cefotaxime. Cefoperazone, cefuroxime, and ceftazidime were inactive. All were relatively active against anaerobic cocci, and Cl. perfringens. Ceftizoxime, cefotaxime, cefoxitin, and cefoperazone were only moderately active against non-perfringens clostridia, while moxalactam, cefuroxime, and ceftazidime were inactive. Cefoxitin, moxalactam, and ceftazidime were inactive against lactobacilli, for which cefotaxime was the most active agent.
These comparative data are in general agreement with those of Rolfe & Finegold (1981) . Rolfe & Finegold (1981) also found that these cephalosporins including ceftizoxime were poorly active against Cl. difficile, which is associated with antibioticassociated diarrhoea and pseudomembranous colitis. Considering the pharmacokinetic attributes and attainable serum and tissue concentrations of ceftizoxime, the in-vitro susceptibility data summarized here would support the potential usefulness of ceftizoxime in the treatment of anaerobic infections. Correlation with clinical efficacy is urgently needed. Its markedly expanded spectrum against many aerobic organisms would indicate that ceftizoxime may be an excellent candidate for single-agent therapy for mixed aerobic-anaerobic infections. Further in-vitro studies and controlled clinical trials are clearly indicated.
